Transcode Therapeutics, Inc. (RNAZ)
2025-06-30 | ||||
|---|---|---|---|---|
| Research and development | 2,565,982 | |||
| General and administrative | 1,655,152 | |||
| Total operating expenses | 4,221,134 | |||
| Operating loss | -4,221,134 | |||
| Interest income | 148 | |||
| Currency exchange gain (loss) | -47,487 | |||
| Change in fair value of warrant liabilities | 161,714 | |||
| Grant income | 153,685 | |||
| Total other income (expense) | -55,368 | |||
| Net loss attributable to common stockholders | -4,276,502 | |||
| Earnings per share, basic | -5.13 | |||
| Earnings per share, diluted | -5.13 | |||
| Weighted average number of shares outstanding, basic | 833,654 | |||
| Weighted average number of shares outstanding, diluted | 833,654 | |||